India drops popular Zantac from essential medicine list over cancer concerns

India removes popular Zantac from essential medicine list due to cancer concerns

Tribune press service

Aditi Tandon

New Delhi, September 13

India on Tuesday removed the antacid Ranitidine, popularly sold as Zantac, from the National Essential Medicines List 2022 due to cancer concerns.

Ranitidine is one of 26 drugs removed from the 2015 NLEM version.

Zantac and other ranitidine products contaminated with high levels of NDMA, a probable human carcinogen, may cause many types of cancer, including bladder cancer, colon cancer, and breast cancer. prostate.

In 2019, N-nitrosodimethylamine (NDMA) was identified in ranitidine samples, leading the US FDA to alert the public to potential risks associated with NDMA exposure, including cancer.

The heartburn medicine ranitidine has been widely used in India.

It is a gastrointestinal drug.

The latest version of NLEM drops all forms of Ranitidine: 150mg tablet, oral liquid and injection.

Vice-chairman of the committee that finalized NLEM 2022 YK Gupta said the deletion involves drugs banned by the regulator due to side effects and safety concerns that alter the drug’s risk-benefit balance.


#India #removes #popular #Zantac #essential #medicine #list #due #cancer #concerns

Leave a Comment

Your email address will not be published.